Outcomes of random-start letrozole protocol with PGT-A in women with breast cancer undergoing fertility preservation
Authors:
- 25 July 2023
- journal article
- research article
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 40 (10) , 2401-2408
Abstract
Purpose To compare the cycle characteristics and outcomes of random-start-controlled ovarian stimulation (RSCOS) protocols to the outcomes of standard-start-controlled ovarian stimulation (SSCOS) cycles and to report the utility of PGT-A in these cycles. Methods One hundred and seventeen who underwent SSCOS and 39 who underwent RSCOS for oocyte and/or embryo cryopreservation before breast cancer chemotherapy were retrospectively evaluated. Mean number of embryos and blastocyst euploidy rates were the main outcome measures. Results A majority of RSCOS cycles were initiated in the luteal phase (66.6% luteal vs. 33.3% follicular). While the total dose of gonadotropins was significantly higher in the RSCOS (3720.8 ± 1230.0 vs. 2345.1 ± 803.6 IU; P < 0.001), the mean number of mature oocytes and embryos was similar to SSCOS. However, there was a trend for a higher number of mean embryos with luteal start RSCOS (6.9 ± 2.7 in late follicular start vs. 9.4 ± 4.2 in luteal start, P = 0.08). PGT-A was performed in 48% of the cases that underwent embryo cryopreservation in RSCOS (12 women, mean age = 35.3 ± 4.1; 87 blastocysts), revealing a euploidy rate of 36.2 ± 22.3% per patient. This rate was comparable to a 45% aneuploidy rate from similarly aged published data. Of the 7 RSCOS patients who returned for frozen embryo transfer, 5 delivered and one has an ongoing pregnancy, while in SSCOS, 18 out of 40 cycles resulted in live birth. Conclusion Our data suggests that RSCOS fertility preservation cycle outcomes are similar to those with SSCOS and result in age-appropriate euploidy rates.Keywords
Funding Information
- National Institute of Child Health and Human Development (RO1 HD053112)
This publication has 28 references indexed in Scilit:
- Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experienceJournal of Assisted Reproduction and Genetics, 2014
- The Endocrinology of the Menstrual Cycle2014
- Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cyclesFertility and Sterility, 2014
- Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patientsFertility and Sterility, 2013
- Effective method for emergency fertility preservation: random-start controlled ovarian stimulationFertility and Sterility, 2013
- Luteal phase GnRHa trigger in random start fertility preservation cyclesJournal of Assisted Reproduction and Genetics, 2012
- Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cyclesFertility and Sterility, 2011
- Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled StudyJournal of Clinical Oncology, 2008
- Letrozole Reduces Estrogen and Gonadotropin Exposure in Women with Breast Cancer Undergoing Ovarian Stimulation before ChemotherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: A pilot studyFertility and Sterility, 2005